Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | DDX3X | O00571 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979264 | 0.84 | HSD17B10 (0.47) | CA12CA1CA2CA9POLB | |
| SCHEMBL3982260 | 0.84 | KDR (0.42) | CA12CA1CA2CA9MAPT | |
| SCHEMBL3986842 | 0.81 | RAD52 (0.50) | CA12CA1CA2CA9GFER | |
| SCHEMBL14259966 | 0.81 | GFER (0.39) | CA12CA1CA2CA9GFER | |
| SCHEMBL3985472 | 0.78 | MAPT (0.51) | L3MBTL1GFERHTTMAPTCYP1A2 | |
| SCHEMBL3979951 | 0.77 | HTT (0.56) | L3MBTL1POLBHTTMAPTCYP1A2 | |
| SCHEMBL3986791 | 0.77 | SIGMAR1 (0.40) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL11289487 | 0.77 | MAPT (0.51) | POLBHTTMAPTCYP1A2CYP2C9 | |
| SCHEMBL11321386 | 0.77 | DDX3X (0.57) | CA12CA1CA2CA9POLB | |
| SCHEMBL3989002 | 0.76 | MAPT (0.52) | CA12CA1CA2CA9GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059511-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008025556-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025556-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | CABLES1, CKS2, CDK2AP1 | L3MBTL1 2898/4885CA12 1890/4885CA1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.